KPV Peptide: Anti-Inflammatory Uses, Research and 2026 FDA Status

• By Healing Maps Editorial Staff
• April 17, 2026September 26, 2026
• Peptide Articles peptide therapy peptide treatment
• With 0 comments

Last reviewed and updated: May 5, 2026 — medically reviewed by Dr. Jonathann Kuo, MD.

KPV is one of the shortest peptides in clinical research. It is just three amino acids long. Despite its tiny size, researchers have studied it for decades as an anti-inflammatory compound with potential applications in wound healing, inflammatory bowel disease, and skin conditions. The FDA is reviewing KPV for the Section 503A Bulk Drug Substances List in July 2026. Here is what the science shows and what the review could mean.

Interested in peptide therapy? Find vetted peptide therapy clinics near you.

KPV is not something any of the national telehealth programs prescribe today, so a licensed local clinic is usually the route. Our peptide telehealth comparison covers what the online programs do carry.

What Is KPV?

KPV is a tripeptide made up of three amino acids: lysine, proline, and valine. It comes from the tail end of a larger molecule called alpha-melanocyte stimulating hormone (α-MSH). Alpha-MSH has well-documented anti-inflammatory properties. Researchers found that the KPV sequence alone preserves much of that anti-inflammatory activity while being smaller, more stable, and easier to deliver. That combination has made KPV a target for translational research into inflammatory conditions where larger biologics are not practical.

How KPV Works

Inflammation is driven in large part by a transcription factor called NF-κB. When cells sense damage or infection, NF-κB activates hundreds of inflammatory genes. KPV appears to interfere with NF-κB signaling. Studies published in journals including Gut have shown that KPV reduces inflammation in intestinal tissue by dampening this pathway. The peptide also has direct antimicrobial activity against certain bacteria and fungi, which may add a second layer of benefit in wound care applications.

Research in Inflammatory Bowel Disease

Some of the most studied applications of KPV are in inflammatory bowel disease. Animal models of colitis have shown that oral KPV reduces disease severity, improves weight recovery, and lowers inflammatory cytokine levels in colon tissue. Researchers have used nanoparticle delivery systems to protect KPV from digestion and target it to inflamed areas of the gut. Early human data is limited but the mechanism is biologically plausible, which is partly why KPV has continued to attract academic and clinical interest.

KPV for Wound Healing and Skin

Wound healing and inflammatory skin conditions are the specific uses the FDA identified for PCAC review. Research suggests KPV applied topically to wounds reduces inflammation and may accelerate tissue repair. Dermatology applications include chronic conditions such as eczema, acne, and hidradenitis suppurativa where inflammation drives much of the disease burden. Peptide clinics sometimes formulate KPV into topical creams for patients with stubborn inflammatory skin disorders that have not responded to standard therapy.

Administration Options

KPV is versatile in how it can be delivered. Oral capsules are common for gut-targeted indications, though bioavailability varies and some formulations use enteric coatings or lipid carriers to improve stability. Topical creams are used for skin and wound applications. Subcutaneous injection is used for systemic anti-inflammatory effect. The right route depends on the indication, the prescribing clinician’s protocol, and the compounding pharmacy’s formulation capabilities.

Safety and Side Effects

KPV has a reassuring safety profile in the research that exists. Its parent molecule, α-MSH, is a natural hormone the body produces daily. KPV itself is short, biodegradable, and does not accumulate in tissue. Reported side effects are minimal and include mild injection site reactions when used subcutaneously. As with any peptide used off-label, long-term safety data in human populations is limited. Clinicians typically screen patients for active infection, autoimmune disease, and pregnancy before starting KPV therapy.

Regulatory Status

KPV is not approved by the FDA for any indication. The review that was pending for most of 2026 has now happened: on July 23, 2026, the FDA’s Pharmacy Compounding Advisory Committee voted 8 to 6 to recommend KPV for the Section 503A bulks list — the same margin BPC-157 and TB-500 received, and against the advice of the agency’s own scientists. That recommendation is non-binding. The FDA still has to accept it and then run notice-and-comment rulemaking, so KPV is not yet lawfully compoundable under 503A and remains a non-FDA-approved compound today. What changed is the direction of travel, not the legal status. Patients should work with a licensed clinician and an accredited compounding pharmacy that can speak to where things stand in their state — we track the vote and what it does and does not do in our report on the PCAC decision.

Cost and Access

KPV is not covered by insurance. Cash-pay costs depend on the formulation. Oral capsules and topical creams often run $100 to $300 per month at typical therapeutic doses. Injectable formulations can cost more. Consultation and lab work from a peptide clinic add to the total cost. Always verify that your provider uses a licensed compounding pharmacy that follows USP 797 standards.

Access is the harder problem. KPV is rarely sold on its own by the telehealth platforms we track — of every vetted program in our coverage, exactly one carries it, and only inside a blend: Live Vital’s Klow, which combines KPV with GHK-Cu, BPC-157 and TB-500 at $149 per month (verified on livevital.io, September 2026). That matters for the gut and skin indications above, because it is also the only product in our coverage that pairs KPV with BPC-157 — the combination patients with inflammatory gut conditions most often ask for by name. Live Vital prescribes after an online medical intake, ships from a licensed U.S. pharmacy, and says it serves all 50 states; a free 15-minute phone consult with its physician, Dr. Patrick Taylor, MD, is available before you commit to anything. Live Vital does not publish the route of administration for its blends, so confirm oral versus injectable with them directly — that detail decides whether a protocol fits a gut indication at all.

Finding a Provider

If you are interested in KPV therapy, look for a licensed clinician who has experience with peptide protocols and can order appropriate labs. Our peptide therapy directory lists verified clinics. For a broader overview of peptide therapy and how it fits into integrative medicine, see our complete guide to peptide treatments.